afatinib
Also known as BIBW2992, Gilotrif®, BIBW 2992, Afatinibum
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.
Key facts
- Drug.licence_EU
- yes
- Drug.protein_bound
- 95%
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 645735594
- Drug.image
- Afatinib2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Afatinib 3D ball-and-stick 4G5P.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Gilotrif, Giotrif, Afanix
- Drug.MedlinePlus
- a613044
- Drug.DailyMedID
- Afatinib
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
~4 min read
Article
6 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- Clinical trials
- References
- External links
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.
It is mainly used to treating cases of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene.
Gallery (2)
Connections
Categories
Antineoplastic drugsAromatic aminesCarboxamidesChemicals using indexlabelsChloroarenesCovalent inhibitorsDimethylamino compoundsDrugboxes which contain changes to verified fieldsDrug has EMA linkDrugs developed by Boehringer IngelheimDrugs with non-standard legal statusECHA InfoCard ID from Wikidata